No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service researchers, biopharma industry representatives, and healthcare professionals. However, the “quick and easy fix” option of price controls invariably comes up. While this option is publicly appealing, the question is what (if any) unintended effects might occur from enacting drug price controls? This white paper will review the published evidence on the relationship between drug price controls and patient health outcomes, especially given the importance of the pharmaceutical industry and drug innovation to the overall social well-being of society.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Fill in your details to get a copy of this whitepaper, and contact us at firstname.lastname@example.org for any questions.